Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
|
|
Axsome Therapeutics, Inc. (AXSM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/15/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/07/2023 |
SC 13G
| Fairmount Funds Management LLC reports a 5% stake in AXSOME THERAPEUTICS, INC. |
| 07/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder in Adults NEW YORK, July 7, 2023 – Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has dosed the first patient in the FOCUS Phase 3 trial of solriamfetol, an investigational treatment for attention deficit hyperactivity disorder in adults. FOCUS is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of ADHD in adults. Approximately 450 patients will be randomized in a 1:1:1 ratio to receive solriamfetol or placebo for 6 weeks. The primary endpoint..." |
|
| 06/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock NEW YORK, June 30, 2023 -- Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced the closing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at the public offering price of $75.00 per share. The aggregate gross proceeds to Axsome, before deducting underwriting discounts and commissions and offering expenses, were $225.0 million. Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its com..." |
|
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/08/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/27/2023 |
8-K
| Quarterly results |
| 02/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Venrock Healthcare Capital Partners II, L.P. reports a 0% stake in AXSOME THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| PFM Health Sciences, LP reports a 3.2% stake in Axsome Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 4.6% stake in AXSOME THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 7.9% stake in Axsome Therapeutics Inc. |
| 02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 12/02/2022 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 11/28/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/24/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/20/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
8-K
| Quarterly results |
| 09/29/2022 |
8-K
| Quarterly results |
| 09/08/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation NEW YORK, Sept. 08, 2022 -- Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced that it has enrolled the first patient in the ADVANCE-2 trial of AXS-05, an investigational treatment for Alzheimer’s disease agitation. ADVANCE-2 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, trial to assess the efficacy and safety of AXS-05 for the treatment of agitation associated with AD. Approximately 350 patients will be randomized in a 1:1 ratio to receive AXS-05 or placebo for 5 weeks. The primary efficacy measure is the Cohen-Mansfield Agitation Inventory . AXS-05 has be..." |
|
|
|
|